Viewing Study NCT05264051


Ignite Creation Date: 2025-12-24 @ 11:47 PM
Ignite Modification Date: 2025-12-25 @ 9:41 PM
Study NCT ID: NCT05264051
Status: RECRUITING
Last Update Posted: 2024-11-14
First Post: 2022-02-22
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
Sponsor: University of Chicago
Organization:

Study Overview

Official Title: MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
Status: RECRUITING
Status Verified Date: 2024-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Detailed Description: Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam.

Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated.

1. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation.
2. Pts. with hepatobiliary neoplasia
3. Pts.undergoing transjugular portosystemic shunt (TIPS) placement
4. Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: